Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3CHRM1CHRM2CHRM3CHRM4ESR1ESR2GABRA1GABRB1GABRG2GBA1HRH1HTR1DHTR2AOPRD1OPRK1OPRM1SLC6A2SLC6A3TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Cadaverine Tartrate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.77 |
| ▸ | TP53 | P04637 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | PDE4A | P27815 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tartaric Acid SCHEMBL30100371 | 1.00 | TSHR (0.77) | TSHRTP53LMNAALDH1A1NFKB1 | |
| Cadaverine Tartrate SCHEMBL7144922 | 0.96 | TSHR (0.71) | TSHRTP53LMNAALDH1A1NFKB1 | |
| Cadaverine Tartrate SCHEMBL981016 | 0.89 | TP53 (0.79) | TSHRTP53LMNANFKB1CYP2C19 | |
| Cadaverine Tartrate SCHEMBL7209361 | 0.89 | TSHR (0.71) | TSHRTP53LMNANFKB1CYP2C19 | |
| Cadaverine Tartrate SCHEMBL8945831 | 0.88 | TSHR (0.83) | TSHRTP53LMNAALDH1A1NFKB1 | |
| Cadaverine Tartrate SCHEMBL4778934 | 0.88 | TSHR (0.83) | TSHRTP53LMNAALDH1A1NFKB1 | |
| Cadaverine Tartrate SCHEMBL848 | 0.88 | TSHR (1.00) | TSHRTP53LMNAALDH1A1NFKB1 | |
| Cadaverine Tartrate SCHEMBL1062721 | 0.88 | TSHR (1.00) | TSHRTP53LMNAALDH1A1NFKB1 | |
| Cadaverine Tartrate SCHEMBL116846 | 0.88 | TSHR (1.00) | TSHRTP53LMNAALDH1A1NFKB1 | |
| Cadaverine Tartrate SCHEMBL1431070 | 0.88 | TSHR (1.00) | TSHRTP53LMNAALDH1A1NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115196640-A | Coal gangue-based mesoporous silicon oxide material and preparation method thereof | 太原理工大学 | 2022-10-18 | — | — | CN | disclosed |
| CN-109810047-A | (R) synthetic method of the chiral intermediate of -3- Phenylpiperidine or/and (S) -3- Phenylpiperidine and Ni Lapani | 上海博邦医药科技有限公司 | 2019-05-28 | — | — | CN | disclosed |
| CN-109563036-A | Novel crystal form of pimavanserin tartrate and preparation method and application thereof | 上海诚妙医药科技有限公司 | 2019-04-02 | — | — | CN | disclosed |
| US-20190084935-A1 | NOVEL POLYMORPH OF PIMAVANSERIN TARTRATE AND PREPARATION METHOD THEREOF AND USE OF SAME | SHANGHAI BEGREAT PHARMATECH (CN) | 2019-03-21 | — | — | US | disclosed |
| CN-108779129-A | Vinorelbine list tartrate and its medicinal usage | 赛比亚斯药业股份公司 | 2018-11-09 | — | — | CN | disclosed |
| US-5569657-A | TREATING CONGESTIVE HEART FAILURE | ORION-YHTYMA OY (FI) | 1996-10-29 | — | — | US | disclosed |
| US-5512571-A | DIASTEREOMERIC INTERMEDIATES WHICH FORM LEVOROTATORYCARDIOTONIC AGENTS HAVING HIGH BIOAVAILABILITY | ORION-YHTYMA OY (FI) | 1996-04-30 | — | — | US | disclosed |
| US-5424428-A | Optical resolution of a drug chemical intermediates 6-(4-amino phenyl)-5-methylpyridazin-3(2H)one by salt-formation with tartaric acid in 2-propanol, desalting by basification | ORION-YHTYMA OY (FI) | 1995-06-13 | — | — | US | disclosed |
| EP-0565546-B1 | (-)-[[4-(1,4,5,6-TETRAHYDRO-4-METHYL-6-OXO-3-PYRIDAZINYL)PHENYL]-HYDRAZONO]PROPANEDINITRILE | ORION YHTYMAE OY (FI) | 1995-03-08 | — | — | EP | disclosed |
| WO-1992012135-A1 | (-)-[[4-(1,4,5,6-TETRAHYDRO-4-METHYL-6-OXO-3-PYRIDAZINYL)PHENYL]-HYDRAZONO]PROPANEDINITRILE | Orion-Yhtymä Oy (FI) | 1992-07-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190084935-A1 | NOVEL POLYMORPH OF PIMAVANSERIN TARTRATE AND PREPARATION METHOD THEREOF AND USE OF SAME | PIM1, CYP4F11, CYP4A11 | TSHR 3466/4885TP53 349/4885LMNA 2216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.